Epidemiology and Nosological Independence
Chronic lymphocytic leukemia is one of the most common hemoblastoses in the older age group. Epidemiological data show that the peak incidence occurs between 50 and 60 years of age. In individuals under 40, this pathology is extremely rare. It is worth noting that among all leukemias diagnosed in patients over 60, chronic lymphocytic leukemia accounts for about half of all cases.
From a pathological anatomy perspective, B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma are considered similar neoplasms. The main difference between these two conditions lies in the localization of the pathological process: a diagnosis of chronic lymphocytic leukemia is established when tumor cells are obligatorily found in the peripheral blood.
Blood Picture and Bone Marrow Changes
Since the disease always originates in the bone marrow, primary pathological processes unfold there. Bone marrow examination reveals pronounced lymphocytosis — lymphocytes account for more than 30% of all cells.
The release of the tumor clone into the bloodstream dramatically alters the peripheral blood picture. Massive leukocytosis develops: the leukocyte count can reach enormous values — up to $100 \times 10^9$/L or even higher. Concurrently, absolute lymphocytosis is observed, exceeding 5,000 cells per 1 µL.
Cell morphology in this disease is quite specific. The tumor elements are mature, almost monomorphic small lymphocytes. Under the microscope, they are characterized by dark, rounded nuclei and a very narrow rim of cytoplasm.
A characteristic feature of chronic lymphocytic leukemia in a blood smear is the presence of Gumprecht shadows (smudge cells). They appear as amorphous smudges with irregular contours located in place of destroyed cells. The phenomenon of their formation is explained by the fact that tumor lymphocytes have reduced mechanical resistance and easily break down due to physical impact during smear preparation.
Pathogenesis, Immune Status, and Clinical Features
The development of chronic lymphocytic leukemia is accompanied by systemic involvement of the body. Pathological cells disseminate from the bone marrow through the bloodstream, and the liver, spleen, and lymph nodes become target organs almost every time.
The clinical picture is largely determined by impairments in the patient's immune status:
- Hypogammaglobulinemia. A drop in the levels of normal serum immunoglobulins (Ig) is observed, making the body vulnerable.
- Paraproteinemia. Pathological immunoglobulins produced by tumor clones circulate in the blood.
Already in the early stages of the disease, approximately 10% of patients may develop severe complications, primarily autoimmune hemolytic anemia and thrombocytopenia. In the late stages of the disease, when tumor masses totally replace normal hematopoietic tissue, pancytopenia naturally develops — a critical decrease in the levels of all blood cell lines.
Briefly: answers to topical questions
Which cytogenetic mutations and chromosomal aberrations are most frequently detected in chronic lymphocytic leukemia?
In chronic lymphocytic leukemia, the primary cytogenetic marker is the 17p deletion, as well as mutations in the TP53 gene.
- 17p deletion (del(17p)) is a negative prognostic marker that determines treatment choice.
- TP53 gene mutations (TP53) cause a mechanism of resistance to therapy due to the loss of gene function. They can occur either in combination with the deletion or as isolated mutations.
The criterion for the presence of a mutation is an allele burden exceeding 10%.
To remember the main morphological marker of CLL, imagine that the tumor lymphocytes are so "fragile" that they burst when a drop of blood is smeared on a glass slide. Only "shadows" remain of them — Gumprecht shadows (smudge cells).
Class and exam questions
What is the main difference between chronic lymphocytic leukemia and small lymphocytic lymphoma?
These neoplasms are nearly identical in cellular composition. The key difference is that in chronic lymphocytic leukemia, tumor cells are found in large numbers in the peripheral blood.
What are Gumprecht shadows (smudge cells)?
These are specific smudges with irregular contours that remain in place of destroyed cells. They appear in the blood smear because tumor lymphocytes are very easily destroyed by mechanical impact.
Why is the immune status impaired in this disease?
The pathological cell clone crowds out normal lymphocytes, leading to a decrease in serum immunoglobulin levels. Meanwhile, the tumor cells themselves can produce defective immunoglobulins, causing paraproteinemia.
What complications are characteristic of early and late stages?
In 10% of patients, autoimmune hemolytic anemia and thrombocytopenia develop in the early stages. In late stages, due to total bone marrow involvement, pancytopenia occurs.
What else to study on this topic
- Mechanisms of development of autoimmune hemolytic anemia and thrombocytopenia in CLL.
- Pathogenesis of pancytopenia formation in the late stages of the disease.
- Morphological changes in the liver, spleen, and lymph nodes during tumor infiltration.
- The nature of paraproteinemia: synthesis of pathological immunoglobulins by tumor clones.
Master the entire topic in the "Pathological Anatomy" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Chronic lymphocytic leukemia" and 4,414 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 153 video lessons on the subject
Other topics in Hematopoietic System Diseases
Free video lessons: pathological anatomyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.